Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (4429)	6/3/1998 11:11:00 PM
From: ALL	Read Replies (3) \| Respond to of 6136

PaineWebber Technology & Growth Conference Highlights: Presenter: Peter Johnson, CEO 1) Currently 921 Employees: 143 Marketing; 247 Development; 355 Research; 176 Administrative. 2) As IMS data is projected based on 20,000 retail pharmacies, script data may contain some statistical noise. 3) In March, Viracept had 40% of US PI dollar sales. 4) A chart highlighted that AGPH has the highest PI market share among physicians whose practices have a high concentration of HIV+ patients. On the other hand, AGPH has a higher share than both Fortovase and Norvir but less than Crixivan among those physicians who do not specialize in HIV. Also, Viracept has a lower market share among whites than blacks and hispanics. As reported earlier on this board, AGPG will direct additional marketing resources to those areas with weaker market share. As of 4/98 Crixivan had 34% prescription market share versus Viracept's 32.2%. Viracept should overtake Crixivan as the leading PI in a few months if current trends continue. 5) Dual PI therapy, which is currently 8-12%, should double in the next year. As such, the PI market is not a zero-sum game. 6) Viracept should receive Canandian approval in the second half of 1998. AGPH will market the product with JT receiving 1/2 of the profits, as in the US. The Canadian market should be 5 to 10% of the US market. 7) The biggest reason for combination therapy failure is non-compliance. Mr. Johnson stated that Merck basically made a representation that failure of one PI would result in failure of all PIS. Research to date has not supported this representation. 8) AGPH does not know European sales of Viracept. However, orders by Roche have exceeded expectations. As a note, 50% of Crixivan sales are outside of the US. 9) Viracept margins should be 70% next year. 10) Mr. Johnson stated that if all went well, AG3340 could be approved in 2000. I think the Dow Jones story, while not totally inaccurate, was taken out of context. At high doses, AG3340 eradicated tumors in rodent models. 11) On average, 50% of all tumors are p53-. AG2034 Gart Inhibitor has a p53- target. 12) AG 7088 Human Rhinovirus 3c Protease will initially be a nasal spray.